Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
Journal for ImmunoTherapy of Cancer · 2023
DOI: 10.1136/jitc-2023-006947 ↗Kurz gefasst
Leitlinie in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2023. Verfasst von Anna C Pavlick und 22 weiteren Autor:innen. Beteiligte Einrichtung: Weill Cornell Medicine, New York, New York, USA acp9008@med.cornell.edu. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms. Die Arbeit wurde bisher 68-mal zitiert (Crossref) und nennt 281 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Since the first approval for immune checkpoint inhibitors (ICIs) for the treatment of cutaneous melanoma more than a decade ago, immunotherapy has completely transformed the treatment landscape of this chemotherapy-resistant disease. Combination regimens including ICIs directed against programmed cell death protein 1 (PD-1) with anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) agents or, more recently, anti-lymphocyte-activation gene 3 (LAG-3) agents, have gained regulatory approvals for the treatment of metastatic cutaneous melanoma, with long-term follow-up data suggesting the possibility of cure for some patients with advanced disease. In the resectable setting, adjuvant ICIs prolong recurrence-free survival and several are FDA-approved. Although not yet approved, neoadjuvant ICIs have also shown to improve event-free survival and remains an ongoing area of investigation. Other immunotherapy strategies, such as oncolytic virotherapy for injectable cutaneous melanoma, bispecific T-cell engager therapy for HLA-A*02:01 genotype-positive uveal melanoma, and lifileucel, an autologous tumor-infiltrating lymphocyte therapy, for unresectable or metastatic melanoma are also available to patients. Despite the remarkable efficacy of these regimens for many patients with cutaneous melanoma, traditional immunotherapy biomarkers (ie, programmed death-ligand 1 expression, tumor mutational burden, T-cell infiltrate and/or microsatellite stability) have failed to reliably predict response. Furthermore, ICIs are associated with unique toxicity profiles, particularly for the highly active combination of anti-PD-1 plus anti-CTLA-4 agents. The Society for Immunotherapy of Cancer (SITC) convened a panel of experts to develop this clinical practice guideline on immunotherapy for the treatment of melanoma, including rare subtypes of the disease (eg, uveal, mucosal), with the goal of improving patient care by providing guidance to the oncology community. Drawing from published data and clinical experience, the Expert Panel developed evidence- and consensus-based recommendations for healthcare professionals using immunotherapy to treat melanoma, with topics including therapy selection in the advanced and perioperative settings, intratumoral immunotherapy, when to use immunotherapy for patients with BRAF V600-mutated disease, management of patients with brain metastases, evaluation of treatment response, special patient populations, patient education, quality of life, and survivorship, among others.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Weill Cornell Medicine, New York, New York, USA acp9008@med.cornell.edu.
- Department of Surgery Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Melanoma Disease Center, Dana Farber Cancer Institute, Boston, Massachusetts, USA.
- Hillman Cancer Center, University of Pittsburg Medical Center, Pittsburgh, Pennsylvania, USA.
- Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington, District of Columbia, USA.
- The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, California, USA.
Zitieren
APA
Pavlick, A. C., Ariyan, C. E., Buchbinder, E. I., Davar, D., Gibney, G. T., Hamid, O., Hieken, T. J., Izar, B., Johnson, D. B., Kulkarni, R. P., Luke, J. J., Mitchell, T. C., Mooradian, M. J., Rubin, K. M., Salama, A. K., Shirai, K., Taube, J. M., Tawbi, H. A., Tolley, J. K., …, & Sullivan, R. J. (2023). Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2023-006947
Vancouver
Pavlick AC, Ariyan CE, Buchbinder EI, Davar D, Gibney GT, Hamid O, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0. Journal for ImmunoTherapy of Cancer. 2023. doi:10.1136/jitc-2023-006947
BibTeX
@article{Pavlick2023,
author = {Pavlick, Anna C and Ariyan, Charlotte E and Buchbinder, Elizabeth I and Davar, Diwakar and Gibney, Geoffrey T and Hamid, Omid and Hieken, Tina J and Izar, Benjamin and Johnson, Douglas B and Kulkarni, Rajan P and Luke, Jason J and Mitchell, Tara C and Mooradian, Meghan J and Rubin, Krista M and Salama, April Ks and Shirai, Keisuke and Taube, Janis M and Tawbi, Hussein A and Tolley, J Keith and Valdueza, Caressa and Weiss, Sarah A and Wong, Michael K and Sullivan, Ryan J},
title = {Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2023},
doi = {10.1136/jitc-2023-006947}
}
EUVIMED